Search companies on Owler
Advanced Search
Latest news
Newsfeed
My followed companies
Followed Companies

Turnstone Biologics focuses on developing oncolytic viral immunotherapies and drugs for the treatment of cancer. Read more

16 Followers on Owler
16 Followers on Owler
16 Followers on Owler
16 Followers on Owler

Turnstone Biologics focuses on developing oncolytic viral immunotherapies and drugs for the treatment of cancer. Read more

Sammy Farah's photo - President & CEO of Turnstone Biologics

President & CEO

Sammy Farah

CEO Approval Rating

85/100

Founded:

2015

Status:

PrivateIndependent Company

SIC Code:

2836 NAICS listing »

Est. Annual Revenue
Est. Employees
Sector
Biotechnology
Headquarters

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

The top 10 competitors in Turnstone Biologics' competitive set are Oncolytics, Genelux, TILT Biotherapeutics, Kite Pharma, Inovio, ViraTherapeutics, Juno Therapeutics, bluebird bio, Dendreon, Abivax. Together they have raised over 3.6B between their estimated 5.5K employees. Turnstone Biologics's revenue is the ranked 10th among it's top 10 competitors. The top 10 competitors average 59M. Turnstone Biologics has 100 employees and is ranked 8th among it's top 10 competitors. The top 10 competitors average 221.

Oncolytics is one of Turnstone Biologics's top competitors. Oncolytics is a Public company that was founded in Calgary, Alberta in 1998. Oncolytics is in the Biotechnology field. Oncolytics has 77 fewer employees vs. Turnstone Biologics.

Genelux is perceived as one of Turnstone Biologics's biggest rivals. Genelux was founded in 2001 in San Diego, California. Genelux competes in the Biotechnology industry. Genelux generates $2.2M more revenue than Turnstone Biologics.

TILT Biotherapeutics is a top competitor of Turnstone Biologics. TILT Biotherapeutics's headquarters is in Helsinki, Southern Finland, and was founded in 2013. TILT Biotherapeutics competes in the Biotechnology field. TILT Biotherapeutics generates 55% of Turnstone Biologics's revenue.

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is $6M a good estimate for Turnstone Biologics's revenue?

I don't know

Trending News for Turnstone Biologics and Turnstone Biologics's Competitors

January 21, 2021

Venture Capital Journal

VC-backed Turnstone Biologics buys Myst Therapeutics

Ottawa-based biotechnology company Turnstone Biologics has acquired Myst Therapeutics, a Los Angeles-... See more »

January 21, 2021

BioSpace

INOVIO Announces Pricing of Public Offering of Common Stock - Jan 21, 2021

INOVIO Pharmaceuticals, Inc., a biotechnology company focused on bringing to market precisely designe... See more »

January 21, 2021

Global University Venturing

NexImmune elects to launch initial public offering -

Johns Hopkins University's oncology therapy developer NexImmune has filed to raise up to $86.3m in an... See more »

Acquisitions

No recent acquisitions found related to Turnstone Biologics

Turnstone Biologics Funding History

$11.3M$52.7M$94.8M

Since Turnstone Biologics was founded in 2015, it has participated in 4 rounds of funding. In total Turnstone Biologics has raised $94.8M. Turnstone Biologics' last funding round was on Dec 2019 for a total of $0

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Equity
Dec 2019
--

Takeda Pharmaceutical

Venture Round
Jan 2019
$42.1M

Sixty Degree Capital

Series B
Nov 2016
$41.4M
Series A
Oct 2015
$11.3M

Total Funding: $94.8M

Since Turnstone Biologics was founded in 2015, it has participated in 4 rounds of funding. In total Turnstone Biologics has raised $94.8M. Turnstone Biologics' last funding round was on Dec 2019 for a total of $0

Investments

No recent investments found related to Turnstone Biologics

Turnstone Biologics News

March 2, 2020firstwordpharma

SIGA Announces Collaboration with Turnstone Biologics

SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on t... See more »
March 2, 2020BioSpace

SIGA Announces Collaboration with Turnstone Biologics

SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on t... See more »
December 20, 2019Biospectrum Asia

Takeda, Turnstone Biologics to develop novel viral immunotherapies

Takeda, Turnstone Biologics to develop Novel Viral Immunotherapies... See more »
December 19, 2019PharmaLive

Takeda Strikes Potential $1 Billion Oncology Deal with Turnstone

One day after Takeda Pharmaceutical and Cerevance teamed up to tackle diseases of the gastrointestina... See more »
November 30, 2018PharmiWeb

Turnstone Biologics Unveils Novel Vaccinia Oncolytic Viral Immunotherapy Platform

Turnstone Biologics Unveils Novel Vaccinia Oncolytic Viral Immunotherapy PlatformTurnstone B...Turnst... See more »
September 4, 2018PipelineReview

Turnstone Biologics and the La Jolla Institute for Allergy and Immunology Enter into Strategic Collaboration for Personalized Neoantigen Immunotherapies

Turnstone Biologics, a clinical-stage immuno-oncology company developing the next generation of oncol... See more »
August 9, 2018BioPortfolio

Turnstone Biologics to Present at the 2018 Wedbush PacGrow Healthcare Conference

Turnstone Biologics a clinicalstage immunooncology company developing the next generation of oncolyti... See more »

Turnstone Biologics Press Releases

November 1, 2016Blackbird

FACIT Start-up Turnstone Biologics Closes USD $41M Financing

OrbiMed, Versant-led round continues commercialization success for Turnstone's cancer therapies TORON... See more »
October 28, 2015PR NEWSWIRE

Turnstone Biologics Completes Series A Financing Led by Versant Ventures, Strengthens Management Team

Investment accelerates robust clinical development of oncolytic viral immunotherapy pipeline TORONTO,... See more »
October 28, 2015CNW GROUP

FACIT Startup Turnstone Biologics Closes $11M Financing, Secures Additional Capital Commitment, and Adds Strong Management

Versant Ventures-led investment accelerates development, broadens oncolytic viral immunotherapy poten... See more »

Social Media

Headquarters

12 York Street, 3rd Floor

Ottawa, OntarioK1N 5S6

613-421-8930

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Turnstone Biologics focuses on developing oncolytic viral immunotherapies and drugs for the treatment of cancer. Turnstone Biologics was founded in 2015. Turnstone Biologics' headquarters is located in Ottawa, Ontario, CA K1N 5S6. It has raised 94.8M ...

CEO

Turnstone Biologics's President & CEO, Sammy Farah, currently has an approval rating of 85%. Turnstone Biologics's primary competitors are Oncolytics, Genelux & TILT Biotherapeutics.

Website

turnstonebio.com

Frequently Asked Questions about Turnstone Biologics

  1. When was Turnstone Biologics founded?

    Turnstone Biologics was founded in 2015

  2. Who is Turnstone Biologics's CEO?

    Turnstone Biologics's CEO is Sammy Farah

  3. How much revenue does Turnstone Biologics generate?

    Turnstone Biologics generates $6M in revenue

  4. How much funding does Turnstone Biologics have?

    Turnstone Biologics has historically raised $94.8M in funding

  1. Where is Turnstone Biologics's headquarters?

    Turnstone Biologics's headquarters is in Ottawa Ontario, CA

  2. How many employees does Turnstone Biologics have?

    Turnstone Biologics has 100 employees

  3. What sector does Turnstone Biologics operate in?

    Turnstone Biologics is in Biotechnology

  4. Who are Turnstone Biologics's competitors?

    Turnstone Biologics's top competitors are Oncolytics, Genelux, TILT Biotherapeutics
Stay up-to-date with the latest news on Turnstone Biologics

© 2021 Owler, Inc.